Aclaris Therapeutics Announces Board and Executive Changes
Ticker: ACRS · Form: 8-K · Filed: Mar 19, 2024 · CIK: 1557746
| Field | Detail |
|---|---|
| Company | Aclaris Therapeutics, INC. (ACRS) |
| Form Type | 8-K |
| Filed Date | Mar 19, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.00001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-changes, executive-compensation, governance
Related Tickers: ACRS
TL;DR
Aclaris Therapeutics adds a director and revises CMO contract.
AI Summary
Aclaris Therapeutics, Inc. announced on March 14, 2024, changes in its board of directors and executive compensation. Specifically, Dr. Karen L. Smith was appointed as a Class II Director, and the company entered into a new employment agreement with its Chief Medical Officer, Dr. Patrick A. Flaherty, effective March 14, 2024.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy or leadership focus, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: low — The filing details routine corporate governance changes and executive compensation adjustments, which typically carry low immediate risk.
Key Players & Entities
- Aclaris Therapeutics, Inc. (company) — Registrant
- Dr. Karen L. Smith (person) — Appointed Class II Director
- Dr. Patrick A. Flaherty (person) — Chief Medical Officer with new employment agreement
- March 14, 2024 (date) — Date of earliest event reported
FAQ
Who was appointed as a new director to Aclaris Therapeutics' board?
Dr. Karen L. Smith was appointed as a Class II Director.
What is the effective date of the reported changes?
The earliest event reported is dated March 14, 2024.
What specific executive role had a new employment agreement entered into?
The Chief Medical Officer, Dr. Patrick A. Flaherty, entered into a new employment agreement.
What is Aclaris Therapeutics' state of incorporation?
Aclaris Therapeutics, Inc. is incorporated in Delaware.
What is the principal executive office address for Aclaris Therapeutics?
The address is 701 Lee Road, Suite 103, Wayne, PA 19087.
Filing Stats: 551 words · 2 min read · ~2 pages · Grade level 13 · Accepted 2024-03-19 16:30:39
Key Financial Figures
- $0.00001 — ange on which Registered Common Stock, $0.00001 par value ACRS The Nasdaq Stock Mar
Filing Documents
- acrs-20240314x8k.htm (8-K) — 35KB
- 0001558370-24-003572.txt ( ) — 152KB
- acrs-20240314.xsd (EX-101.SCH) — 3KB
- acrs-20240314_lab.xml (EX-101.LAB) — 16KB
- acrs-20240314_pre.xml (EX-101.PRE) — 10KB
- acrs-20240314x8k_htm.xml (XML) — 5KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ACLARIS THERAPEUTICS, INC. By: /s/ Kevin Balthaser Date: March 19, 2024 Kevin Balthaser Chief Financial Officer 3